Comparing across regions over the period 2007 - 2016, the United States has remained the principal region for the first launch of New Molecular Entities (NME) with 53% of all New Molecular Entities. The United States retains a key innovative draw for new medicines over other regions around the world. In 2016 Europe had 16% of NMEs first launched. An uptake in New Molecular Entities first launched in the Rest of the World including China, Korea and Russia was seen in 2016.
Annual surveys of the global pharmaceutical industry were undertaken to identify all new molecular entities introduced for the first time anywhere in the world. Presented is the proportion of each year’s output between 2007- 2016 according to the geographical region of the first launch.
Source: 2016 CMR Factbook from Clarivate Analytics; Drawn from the Annual Survey of New Molecular Entity First Launches / New Medicine Launches 2015. A complete guide to New Molecular Entities (NMEs) launched world-wide and reproduced with permission.